• 14 June 2010
  • News
  • By

Back on growth track

Bharat Serums and Vaccines (BSV) registered an impressive 25 percent growth in 2009-10 as against a flat growth of 2008-09

Bharat Serums

Dr Bharat Daftary (CMD)

R&D, manufacturing and marketing of biological, pharmaceutical and biotechnology products

Startup Year:

Hoechst House, 16th Floor, Nariman Point, Mumbai-400021, Maharashtra



Fiscal 2009-10 saw Bharat Serums and Vaccines (BSV) registering a growth of 25 per cent clocking a total sales turnover of Rs 175 crore as against Rs 140 crore in fiscal 2008-09. The BSV registered a good growth as against the industry growth of 16 percent in 2009.

BSV has received funding from the Malaysian firm OrbiMed to fecilitate the next stage of growth. “Investment in BSV by one of the largest healthcare focused funds validates our company's research, manufacturing and marketing capabilities and distinctive business model. OrbiMed's investment and involvement will considerably facilitate the next stage of BSV's growth,” stated Bharat Daftary, chairman and managing director of BSV.

“BSV continues to be at the forefront of proprietary research of value added therapeutics and the investment by a knowledgeable investor like OrbiMed acts a booster for our self belief, long term value generation and growth prospects,” Dr Daftary added.

The company manufactures and markets biological, pharmaceutical and biotechnology products and has in its portfolio over 25 brands which includes Plasma Derivatives, Monoclonals, Equine Antitoxins And Serums, Cardiovascular, Antimicrobials, Antifungals, Anesthetics, Hormones. Over the years, BSV has put in emphasis on its R&D operations both in India and overseas. It has three distinct R&D divisions working extensively on NDDS, biotechnology and equine products.

In April 2010, Piramal Healthcare Limited, acquired BSV's injectible anesthetic products business. The former signed a definitive agreement to acquire the Pune-based Bharat Serum's injectible anaesthetic products business including – propofol, bupivacaine and atracurium besylate.

BSV holds a significant market share in India for plasma derivatives. The product portfolio comprises a wide range of products such as plasma derivatives, monoclonals, hormones, equine antitoxins and serums, antifungals, anaesthetics, cardiovascular and diagnostic products.

BSV has allocated substantial resources towards the research and development of pharmaceutical products in the areas of Novel Drug Delivery, Biotechnology and Biologicals. BSV has a pipeline of novel products and “difficult generics” and is in discussions with potential partners for commercialization of these products.

The novel products include certain New Biological Entities and Novel Drug Delivery systems. The patents for these products will belong to BSV.

The anti-infective product is from the drug delivery research and comes under the category of difficult generics. BSV is seeking various partnering models including licensing, co-development, to commercialize its products.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email